semaglutide in chronic kidney disease Full article: Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients

significant 24% reduction in kidney disease progression and death related to kidney and cardiovascular causes in those treated with semaglutide compared to a placebo

27.83

★★★★☆4.8 (126)

Design and discovery of a highly potent ultralong-acting GLP-1 and glucagon co-agonist for attenuating renal fibrosis

24.87

★★★★★4.9 (98)

Semaglutide: A Breakthrough for Chronic Kidney Disease

20.44

★★★★★5.0 (157)

🔴Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants

27.22

★★★★★4.7 (84)

FDA Approves Semaglutide to Reduce Kidney Disease, Cardiovascular Death Risk in Adults With Type 2 Diabetes, Chronic Kidney Disease

23.98

★★★★★4.9 (203)

Presented at #ERA24: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss

20.93

★★★★★5.0 (176)

FDA approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

22.40

★★★★★4.8 (132)